{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:14:47Z","timestamp":1773929687089,"version":"3.50.1"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bioorg.2025.109397","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T16:08:21Z","timestamp":1765901301000},"page":"109397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hydrophilic and lipophilic colchicinoid formulations for therapy of liver fibrosis in murine model"],"prefix":"10.1016","volume":"169","author":[{"given":"Elena V.","family":"Svirshchevskaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina S.","family":"Shchegravina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iuliia A.","family":"Gracheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryia V.","family":"Konovalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei B.","family":"Akopov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria S.","family":"Tretiakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia D.","family":"Rysina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Zapevalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-G\u00fcnther","family":"Schmalz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry O.","family":"Koroev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey E.","family":"Gavryushin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena L.","family":"Vodovozova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey Yu.","family":"Fedorov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109397_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2025.109397_bb0010","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: the virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.109397_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","article-title":"Alcohol, liver disease and the gut microbiota","volume":"16","author":"Bajaj","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/nu10010009","article-title":"Nutrition and liver disease","volume":"10","author":"Mandato","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.bioorg.2025.109397_bb0025","first-page":"1","article-title":"Current and emerging approaches for hepatic fibrosis treatment","volume":"2021","author":"Li","year":"2021","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.bioorg.2025.109397_bb0030","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: First Approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2025.109397_bb0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jhep.2020.04.033","article-title":"Danger signals in liver injury and restoration of homeostasis","volume":"73","author":"Han","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s43152-021-00030-3","article-title":"Extracellular matrix Remodeling in chronic liver disease","volume":"2","author":"Ortiz","year":"2021","journal-title":"Curr. Tissue Microenviron. Reports."},{"key":"10.1016\/j.bioorg.2025.109397_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232315292","article-title":"Activated hepatic stellate cells in hepatocellular carcinoma: their role as a potential target for future therapies","volume":"23","author":"Ali","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109397_bb0050","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2741\/887","article-title":"Liver nbsp fibrosis signals leading to the amplification of the fibrogenic hepatic stellate cell","volume":"8","author":"Rippe","year":"2003","journal-title":"Front. Biosci."},{"key":"10.1016\/j.bioorg.2025.109397_bb0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","article-title":"TGF-\u03b2 in progression of liver disease","volume":"347","author":"Dooley","year":"2012","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bioorg.2025.109397_bb0060","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1530-0277.1999.tb04202.x","article-title":"Cytokine regulation of hepatic stellate cells in liver fibrosis","volume":"23","author":"Tsukamoto","year":"1999","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"10.1016\/j.bioorg.2025.109397_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.803037","article-title":"Macrophage polarization and its role in liver disease","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0070","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0075","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1007\/s00018-019-03255-6","article-title":"Dual CCR5\/CCR2 targeting: opportunities for the cure of complex disorders","volume":"76","author":"Fantuzzi","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2025.109397_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2019.105922","article-title":"Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA phase 3 study design","volume":"89","author":"Anstee","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.bioorg.2025.109397_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study","volume":"72","author":"Ratziu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.109397_bb0090","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2025.109397_bb0095","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","article-title":"GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease","volume":"155","author":"Loomba","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bioorg.2025.109397_bb0100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41401-019-0310-0","article-title":"WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice","volume":"41","author":"Gao","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2025.109397_bb0105","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2025.109397_bb0110","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3389\/fphar.2018.01438","article-title":"Bicyclol attenuates liver inflammation induced by infection of hepatitis C virus via repressing ROS-mediated activation of MAPK\/NF-\u03baB Signaling pathway","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fphar.2020.00463","article-title":"Bicyclol attenuates acute liver injury by activating autophagy, anti-oxidative and anti-inflammatory capabilities in mice","volume":"11","author":"Zhao","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10068-017-0287-8","article-title":"Quercetin and its metabolites protect hepatocytes against ethanol-induced oxidative stress by activation of Nrf2 and AP-1","volume":"27","author":"Lee","year":"2018","journal-title":"Food Sci. Biotechnol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0125","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0192623311418680","article-title":"Role of quercetin in preventing thioacetamide-induced liver injury in rats","volume":"39","author":"de David","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0130","first-page":"6169","article-title":"Quercetin prevents alcohol-induced liver injury through targeting of PI3K\/Akt\/nuclear factor-\u03baB and STAT3 signaling pathway","volume":"14","author":"Zhu","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.bioorg.2025.109397_bb0135","first-page":"2377","article-title":"Andrographolide protects liver cells from H2O2 induced cell death by upregulation of Nrf-2\/HO-1 mediated via adenosine A2a receptor signalling","volume":"2016","author":"Mittal","year":"1860","journal-title":"Biochim. Biophys. Acta - Gen. Subj."},{"key":"10.1016\/j.bioorg.2025.109397_bb0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/antiox8120571","article-title":"Andrographolide","volume":"8","author":"Mussard","year":"2019","journal-title":"A Natural Antioxidant: An Update, Antioxidants."},{"key":"10.1016\/j.bioorg.2025.109397_bb0145","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.toxrep.2022.04.007","article-title":"Hepatoprotective activity of andrographolide possibly through antioxidative defense mechanism in Sprague-Dawley rats","volume":"9","author":"Mondal","year":"2022","journal-title":"Toxicol. Reports."},{"key":"10.1016\/j.bioorg.2025.109397_bb0150","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/hep.25938","article-title":"Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent","volume":"56","author":"Aoyama","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.109397_bb0155","doi-asserted-by":"crossref","first-page":"eabg9241","DOI":"10.1126\/sciadv.abg9241","article-title":"The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1","volume":"7","author":"Xi","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bioorg.2025.109397_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2019.00056","article-title":"Repurposing pirfenidone for nonalcoholic steatohepatitis-related cirrhosis: a case series","volume":"8","author":"Philips","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0165","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.26790","article-title":"Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha\/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice","volume":"59","author":"Chen","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.109397_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6574010","article-title":"Antifibrotic effect of combination of nilotinib and stem cell-conditioned media on CCl 4 -induced liver fibrosis","volume":"2020","author":"Shiha","year":"2020","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.bioorg.2025.109397_bb0175","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/1440-1681.12286","article-title":"Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight","volume":"41","author":"Shiha","year":"2014","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","article-title":"Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient l-amino acid-defined diet","volume":"315","author":"Kawaguchi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.109397_bb0185","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"22","key":"10.1016\/j.bioorg.2025.109397_bb0190","first-page":"00650","article-title":"Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a phase 2 randomized controlled trial","volume":"S1542-3565","author":"Cai","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13318-015-0316-z","article-title":"Tolerability and pharmacokinetics of Hydronidone, an antifibrotic agent for hepatic fibrosis, after single and multiple doses in healthy subjects: an open-label, randomized, dose-escalating, first-in-human study","volume":"42","author":"Liu","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2025.109397_bb0200","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/biom10030487","article-title":"TGF-\u03b2 Signaling","volume":"10","author":"Tzavlaki","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2025.109397_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.593269","article-title":"Connective tissue growth factor: from molecular understandings to drug discovery","volume":"8","author":"Chen","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0210","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","article-title":"The PDGF\/PDGFR pathway as a drug target","volume":"62","author":"Papadopoulos","year":"2018","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.bioorg.2025.109397_bb0215","first-page":"699","article-title":"TGF-\u03b2 signaling: a complex role in tumorigenesis (review)","volume":"1","author":"Liu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2025.109397_bb0220","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/08977194.2016.1180293","article-title":"The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer","volume":"34","author":"Wang","year":"2016","journal-title":"Growth Factors"},{"key":"10.1016\/j.bioorg.2025.109397_bb0225","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.trecan.2020.12.001","article-title":"Targeting CTGF in Cancer: an emerging therapeutic opportunity","volume":"7","author":"Shen","year":"2021","journal-title":"Trends in Cancer."},{"key":"10.1016\/j.bioorg.2025.109397_bb0230","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.874408","article-title":"New drugs for hepatic fibrosis","volume":"13","author":"Shan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0235","first-page":"755","article-title":"Treatment of liver fibrosis: past, current, and future, world","volume":"15","author":"Zhang","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0240","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.bioorg.2025.109397_bb0245","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.3748\/wjg.v16.i23.2889","article-title":"Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease","volume":"16","author":"Muntoni","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0250","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1034\/j.1600-0676.2001.021002129.x","article-title":"Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis","volume":"21","author":"Rambaldi","year":"2001","journal-title":"Liver"},{"key":"10.1016\/j.bioorg.2025.109397_bb0255","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/(SICI)1099-1263(199705)17:3<145::AID-JAT417>3.0.CO;2-7","article-title":"Trimethylcolchicinic acid decreases liver fibrosis and cholestasis induced by prolonged biliary obstruction in the rat","volume":"17","author":"Muriel","year":"2025","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0260","first-page":"2069","article-title":"Progress in the management of acute colchicine poisoning in adults, intern","volume":"17","author":"Wu","year":"2022","journal-title":"Emerg. Med."},{"key":"10.1016\/j.bioorg.2025.109397_bb0265","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1021\/acs.bioconjchem.9b00051","article-title":"Phospholipidic Colchicinoids as promising prodrugs incorporated into enzyme-responsive liposomes: chemical, biophysical, and enzymological aspects","volume":"30","author":"Shchegravina","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bioorg.2025.109397_bb0270","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2147\/IJN.S24450","article-title":"A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy","volume":"6","author":"Crielaard","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bioorg.2025.109397_bb0275","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejps.2011.08.027","article-title":"Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics","volume":"45","author":"Crielaard","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.109397_bb0280","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.3390\/ijms23031034","article-title":"Liposomal Formulation of a PLA2-Sensitive Phospholipid\u2013Allocolchicinoid Conjugate: Stability and Activity Studies In Vitro","volume":"23","author":"Kobanenko","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109397_bb0285","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1134\/S1068162021050265","article-title":"Cy5-Labeled phosphatidylcholine","volume":"47","author":"Gracheva","year":"2021","journal-title":"Russ. J. Bioorganic Chem."},{"key":"10.1016\/j.bioorg.2025.109397_bb0290","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nprot.2015.017","article-title":"High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers","volume":"10","author":"Mederacke","year":"2015","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.bioorg.2025.109397_bb0295","doi-asserted-by":"crossref","first-page":"C1213","DOI":"10.1152\/ajpcell.00001.2023","article-title":"A simple and effective scaffold for mouse hepatic stellate cell primary culture","volume":"324","author":"Van Le","year":"2023","journal-title":"Am. J. Physiol. Physiol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112724","article-title":"Discovery of dihydrofuranoallocolchicinoids - highly potent antimitotic agents with low acute toxicity","volume":"207","author":"Shchegravina","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109397_bb0305","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1016\/0031-9422(90)87143-I","article-title":"Alkaloids and phenolics of Colchicum turcicum","volume":"29","author":"Husek","year":"1990","journal-title":"Phytochemistry"},{"key":"10.1016\/j.bioorg.2025.109397_bb0310","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/hep.1840150226","article-title":"Ito cell expression of a nuclear retinoic acid receptor","volume":"15","author":"Weiner","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.109397_bb0315","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/21691401.2014.953633","article-title":"Application of liposomes in medicine and drug delivery","volume":"44","author":"Daraee","year":"2016","journal-title":"Artif. Cells, Nanomedicine, Biotechnol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0320","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0325","doi-asserted-by":"crossref","first-page":"10618","DOI":"10.1021\/acs.jmedchem.0c00222","article-title":"Colchicine alkaloids and synthetic analogues: current Progress and perspectives","volume":"63","author":"Gracheva","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109397_bb0330","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejmech.2017.09.055","article-title":"Synthesis and biological evaluation of novel non-racemic indole-containing allocolchicinoids","volume":"141","author":"Shchegravina","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109397_bb0335","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3390\/polym13132045","article-title":"Size-dependent biodistribution of fluorescent Furano-Allocolchicinoid-chitosan formulations in mice","volume":"13","author":"Gracheva","year":"2021","journal-title":"Polymers (Basel)."},{"key":"10.1016\/j.bioorg.2025.109397_bb0340","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/cancers12010144","article-title":"Targeted Nano-drug delivery of colchicine against Colon Cancer cells by means of mesoporous silica nanoparticles","volume":"12","author":"AbouAitah","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.109397_bb0345","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1208\/s12248-008-9078-8","article-title":"Elastic liposomal formulation for sustained delivery of colchicine: In Vitro Characterization and In Vivo Evaluation of Anti-gout Activity","volume":"11","author":"Singh","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.bioorg.2025.109397_bb0350","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4172\/2161-0444.1000401","article-title":"Antitumor activity of Furanoallocolchicinoid-chitosan conjugate","volume":"6","author":"Svirshchevskaya","year":"2016","journal-title":"Med. Chem. (Los. Angeles)."},{"key":"10.1016\/j.bioorg.2025.109397_bb0355","first-page":"251","article-title":"Radiosynthesis and biological evaluation of 68 ga-Labeled colchicine conjugates","volume":"29","author":"Satpati","year":"2014","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.bioorg.2025.109397_bb0360","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejmech.2017.12.029","article-title":"Colchicine prodrugs and codrugs: chemistry and bioactivities","volume":"144","author":"Ghawanmeh","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109397_bb0365","first-page":"1585","article-title":"A convenient entry to new C-7-modified Colchicinoids through Azide alkyne [3+2] cycloaddition: application of ring-contractive rearrangements","volume":"82","author":"Nicolaus","year":"2011","journal-title":"Heterocycles"},{"key":"10.1016\/j.bioorg.2025.109397_bb0370","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00128-2","article-title":"Interactions of liposomes and lipid-based carrier systems with blood proteins: relation to clearance behaviour in vivo","volume":"32","author":"Semple","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bioorg.2025.109397_bb0375","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.colsurfb.2018.02.061","article-title":"Influence of stabilizing components on the integrity of antitumor liposomes loaded with lipophilic prodrug in the bilayer","volume":"166","author":"Tretiakova","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.bioorg.2025.109397_bb0380","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/membranes12111031","article-title":"Spectroscopy study of albumin interaction with negatively charged liposome membranes: mutual structural effects of the protein and the bilayers","volume":"12","author":"Tretiakova","year":"2022","journal-title":"Membranes (Basel)."},{"key":"10.1016\/j.bioorg.2025.109397_bb0385","doi-asserted-by":"crossref","first-page":"19726","DOI":"10.1039\/C6NR05455B","article-title":"Binding of human serum albumin to PEGylated liposomes: insights into binding numbers and dynamics by fluorescence correlation spectroscopy","volume":"8","author":"Kristensen","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.bioorg.2025.109397_bb0390","doi-asserted-by":"crossref","first-page":"8530","DOI":"10.1096\/fj.201802675R","article-title":"Exosomes from activated hepatic stellate cells contain GLUT1 and PKM2: a role for exosomes in metabolic switch of liver nonparenchymal cells","volume":"33","author":"Wan","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2025.109397_bb0395","first-page":"735","article-title":"MMP-3 polymorphism: genetic marker in pathological processes (review)","volume":"3","author":"Santos","year":"2010","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2025.109397_bb0400","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2018.00730","article-title":"In-silico characterization and in-vivo validation of Albiziasaponin-a, Iso-orientin, and Salvadorin using a rat model of Alzheimer's disease","volume":"9","author":"Rasool","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0405","first-page":"G211","article-title":"Role of eosinophils in the initiation and progression of pancreatitis pathogenesis","volume":"314","author":"Manohar","year":"2018","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00011-017-1106-7","article-title":"Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients","volume":"67","author":"Carvalheiro","year":"2018","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bioorg.2025.109397_bb0415","doi-asserted-by":"crossref","first-page":"30","DOI":"10.21037\/dmr-21-87","article-title":"Role of the chemokine system in liver fibrosis: a narrative review","volume":"5","author":"Poulsen","year":"2022","journal-title":"Dig. Med. Res."},{"key":"10.1016\/j.bioorg.2025.109397_bb0420","first-page":"548","article-title":"Interleukin-6 blockers improve inflammation-induced lipid metabolism impairments but induce liver fibrosis in collagen-induced arthritis, endocrine, Metab. Immune Disord. - drug","volume":"23","author":"Denga","year":"2023","journal-title":"Targets"},{"key":"10.1016\/j.bioorg.2025.109397_bb0425","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.11.046","article-title":"IL-2 leaves its mark in cirrhosis","volume":"74","author":"Burton","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.bioorg.2025.109397_bb0430","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1002\/hep.30061","article-title":"Interleukin 2 promotes hepatic regulatory T cell responses and protects from biliary fibrosis in murine sclerosing cholangitis","volume":"68","author":"Taylor","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.bioorg.2025.109397_bb0435","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2024.02.032","article-title":"Endothelial POFUT1 controls injury-induced liver fibrosis by repressing fibrinogen synthesis","volume":"81","author":"He","year":"2024","journal-title":"J. Hepatol."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:13:06Z","timestamp":1773918786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825012775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":87,"alternative-id":["S0045206825012775"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109397","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydrophilic and lipophilic colchicinoid formulations for therapy of liver fibrosis in murine model","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109397","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109397"}}